The European Commission has authorized Pfizer and BioNTech's updated COVID-19 vaccine for the 2026-2027 season, targeting the XFG variant of the virus. This vaccine is approved for individuals aged 6 months and older and is based on strong clinical and real-world data showing effective immune responses against current and emerging variants. Manufacturing has already begun to meet anticipated demand for the upcoming respiratory disease season. The approval covers all EU member states plus Iceland, Liechtenstein, and Norway, ensuring broad access across Europe.
Pfizer is rated a buy not because it is deeply undervalued now, but due to a disconnect between management's optimistic long-term growth outlook and the market's flat earnings expectations. While consensus models predict a revenue and earnings declin...
Pfizer faces significant revenue declines as key drug patents expire, but aims to maintain stable earnings through 2028 with a new drug pipeline and cost-saving measures targeting up to $4 billion in savings. The company projects 2026 revenues of $61...
